A topical analgesic and astringent combination used primarily for the symptomatic relief of pain and inflammation associated with minor mouth and throat conditions. Choline salicylate is a non-steroidal anti-inflammatory drug (NSAID) derivative, while tannic acid provides astringent and protein-precipitating properties, helping to tighten tissues and reduce minor bleeding.
Adult: Apply a small amount (approx. 0.5-1 cm of gel) directly to the affected area in the mouth or throat using a clean fingertip or cotton swab. Gently massage. Use every 3-4 hours as needed, after meals and at bedtime. Do not exceed 6 applications in 24 hours.
Note: For best results, apply to clean, dry mucosa. Avoid eating or drinking for at least 15-20 minutes after application. Do not swallow deliberately. For throat pain, apply to the back of the tongue or tonsillar pillars to allow spreading by saliva.
The combination provides dual action: Choline Salicylate inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis responsible for pain and inflammation at the nerve endings in the oral mucosa. Tannic Acid acts as an astringent, precipitating surface proteins to form a protective layer, reducing tissue edema, shrinking capillaries, and providing a mild hemostatic effect.
Pregnancy: Category D (as per salicylate component). Avoid especially in the third trimester due to risk of premature closure of ductus arteriosus, prolonged labor, and potential bleeding risks in mother and neonate. Use only if clearly needed and potential benefit justifies the risk, under strict medical supervision.
Driving: Unlikely to affect ability. However, if systemic absorption is significant (overuse), symptoms like dizziness or tinnitus may impair driving.
| Anticoagulants (Warfarin, Acenocoumarol) | Increased risk of bleeding due to additive antiplatelet effect and potential displacement from protein binding. | Major |
| Other NSAIDs (Ibuprofen, Diclofenac) | Increased risk of GI toxicity and reduced renal blood flow. | Moderate |
| Methotrexate | Reduced renal clearance of methotrexate, increasing its toxicity. | Major |
| Sulfonylureas (Glibenclamide, Glimepiride) | Salicylates may potentiate hypoglycemic effect. | Moderate |
| ACE Inhibitors (Enalapril, Ramipril) | Attenuation of antihypertensive effect and potential worsening of renal function. | Moderate |
| Valproic Acid | Increased serum levels of valproic acid due to protein-binding displacement. | Moderate |
| Corticosteroids (Prednisolone) | Increased risk of GI ulceration; corticosteroids may reduce salicylate levels. | Moderate |
Same composition (Choline Salicylate (8.7% w/w) + Tannic Acid (10% w/w)), different brands: